NCT00882882View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

June 30, 2001

Study Completion Date

June 30, 2001

Conditions
Type II Diabetes
Interventions
DRUG

Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

DRUG

Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC

DRUG

GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

DRUG

GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00882882 - To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter